{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T22:40:19Z","timestamp":1782600019407,"version":"3.54.5"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Selected chronic myeloid leukemia (CML) patients may discontinue their tyrosine kinase inihibitor (TKI) in an attempt to achieve sustained treatment-free remission (TFR), which mitigates therapy-related side effects and limits treatment costs. TFR has been extensively studied following the discontinuation of adenosine triphosphate (ATP) \u2013 competitive TKI. However, there is minimal data concerning TFR after the discontinuation of the novel TKI asciminib. Here, we present two CML patients intolerant to multiple ATP-competitive TKIs who achieved a deep molecular response (DMR) during asciminib treatment and sustained this remission after asciminib discontinuation. One of the cases developed transient myalgia and arthralgia after asciminib discontinuation consistent with a TKI withdrawal syndrome. Both patients have been free of molecular relapse for more than at least 8 months after TKI discontinuation without increase in molecular BCR::ABL1 signal. These two cases provide proof of principle that sustained TFR after discontinuing asciminib in CML patients is feasible.<\/jats:p>","DOI":"10.1007\/s00277-024-06170-4","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T04:22:04Z","timestamp":1736482924000},"page":"2065-2068","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sustained treatment-free remission in two chronic myeloid leukemia patients after asciminib discontinuation: a report of two cases"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2198-2137","authenticated-orcid":false,"given":"Arjen","family":"Yousefi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2139-3547","authenticated-orcid":false,"given":"Mark-David","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0746-7039","authenticated-orcid":false,"given":"Peter E.","family":"Westerweel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"issue":"4","key":"6170_CR1","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Sau\u00dfele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4):966\u2013984. https:\/\/doi.org\/10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"issue":"3","key":"6170_CR2","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/bjh.16408","volume":"189","author":"S Dulucq","year":"2020","unstructured":"Dulucq S, Astrugue C, Etienne G, Mahon FX, Benard A (2020) Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years. Br J Haematol 189(3):452\u2013468. https:\/\/doi.org\/10.1111\/bjh.16408","journal-title":"Br J Haematol"},{"issue":"7647","key":"6170_CR3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, Marzinzik AL, Pelle X, Donovan J, Zhu W, Buonamici S, Hassan AQ, Lombardo F, Iyer V, Palmer M, Berellini G, Dodd S, Thohan S, Bitter H, Branford S, Ross DM, Hughes TP, Petruzzelli L, Vanasse KG, Warmuth M, Hofmann F, Keen NJ, Sellers WR (2017) The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature 543(7647):733\u2013737. https:\/\/doi.org\/10.1038\/nature21702","journal-title":"Nature"},{"issue":"3","key":"6170_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","volume":"37","author":"A Hochhaus","year":"2023","unstructured":"Hochhaus A, R\u00e9a D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, Apperley JF, Lomaia E, Voloshin S, Turkina A, Kim DW, Abdo A, Fogliatto LM, le Coutre P, Sasaki K, Kim DDH, Saussele S, Annunziata M, Chaudhri N, Chee L, Garc\u00eda-Guti\u00e9rrez V, Kapoor S, Allepuz A, Quenet S, B\u00e9doucha V, Mauro MJ (2023) Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia 37(3):617\u2013626. https:\/\/doi.org\/10.1038\/s41375-023-01829-9","journal-title":"Leukemia"},{"key":"6170_CR5","unstructured":"National Cancer Institute (2017) Common terminology criteria for adverse events (CTCAE) version 5.0.https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Accessed 5 December 2024"},{"issue":"6","key":"6170_CR6","doi-asserted-by":"publisher","first-page":"e496","DOI":"10.1097\/HS9.0000000000000496","volume":"4","author":"CCB Kockerols","year":"2020","unstructured":"Kockerols CCB, Valk PJM, Levin MD, Pallisgaard N, Cornelissen JJ, Westerweel PE (2020) Digital PCR for BCR-ABL1 quantification in CML: current applications in clinical practice. Hemasphere 4(6):e496. https:\/\/doi.org\/10.1097\/HS9.0000000000000496","journal-title":"Hemasphere"},{"issue":"4","key":"6170_CR7","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s12185-024-03816-x","volume":"120","author":"R Yoshimaru","year":"2024","unstructured":"Yoshimaru R, Minami Y (2024) Achievement of deep molecular response and treatment-free remission with asciminib treatment in CML. Int J Hematol 120(4):512\u2013514. https:\/\/doi.org\/10.1007\/s12185-024-03816-x","journal-title":"Int J Hematol"},{"issue":"9","key":"6170_CR8","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/s41375-024-02327-2","volume":"38","author":"P Ernst","year":"2024","unstructured":"Ernst P, Rinke J, Franke GN, Dicker F, Haferlach T, Ernst T, Hochhaus A (2024) Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation. Leukemia 38(9):2037\u20132040. https:\/\/doi.org\/10.1038\/s41375-024-02327-2","journal-title":"Leukemia"},{"issue":"5","key":"6170_CR9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.clml.2018.03.004","volume":"18","author":"M Okada","year":"2018","unstructured":"Okada M, Imagawa J, Tanaka H, Nakamae H, Hino M, Murai K, Ishida Y, Kumagai T, Sato S, Ohashi K, Sakamaki H, Wakita H, Uoshima N, Nakagawa Y, Minami Y, Ogasawara M, Takeoka T, Akasaka H, Utsumi T, Uike N, Sato T, Ando S, Usuki K, Mizuta S, Hashino S, Nomura T, Shikami M, Fukutani H, Ohe Y, Kosugi H, Shibayama H, Maeda Y, Fukushima T, Yamazaki H, Tsubaki K, Kukita T, Adachi Y, Nataduka T, Sakoda H, Yokoyama H, Okamoto T, Shirasugi Y, Onishi Y, Nohgawa M, Yoshihara S, Morita S, Sakamoto J, Kimura S, DADI Trial Group, Japan (2018) Final 3-year results of the Dasatinib Discontinuation Trial in patients with chronic myeloid leukemia who received Dasatinib as a second-line treatment. Clin Lymphoma Myeloma Leuk 18(5):353\u2013360e1. https:\/\/doi.org\/10.1016\/j.clml.2018.03.004","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"6170_CR10","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","volume":"129","author":"D Rea","year":"2017","unstructured":"Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, Gardembas M, Coiteux V, Guillerm G, Legros L, Etienne G, Pignon JM, Villemagne B, Escoffre-Barbe M, Ianotto JC, Charbonnier A, Johnson-Ansah H, Noel MP, Rousselot P, Mahon FX (2017) Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood 129(7):846\u2013854 France Intergroupe des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques. https:\/\/doi.org\/10.1182\/blood-2016-09-742205","journal-title":"Blood"},{"issue":"25","key":"6170_CR11","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1200\/JCO.2014.55.6910","volume":"32","author":"J Richter","year":"2014","unstructured":"Richter J, S\u00f6derlund S, L\u00fcbking A, Dreimane A, Lotfi K, Markev\u00e4rn B, Sj\u00e4lander A, Saussele S, Olsson-Str\u00f6mberg U, Stenke L (2014) Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol 32(25):2821\u20132823. https:\/\/doi.org\/10.1200\/JCO.2014.55.6910","journal-title":"J Clin Oncol"},{"issue":"6","key":"6170_CR12","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3324\/haematol.2015.139899","volume":"101","author":"SE Lee","year":"2016","unstructured":"Lee SE, Choi SY, Song HY, Kim SH, Choi MY, Park JS, Kim HJ, Kim SH, Zang DY, Oh S, Kim H, Do YR, Kwak JY, Kim JA, Kim DY, Mun YC, Lee WS, Chang MH, Park J, Kwon JH, Kim DW (2016) Imatinib Withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica 101(6):717\u2013723. https:\/\/doi.org\/10.3324\/haematol.2015.139899","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06170-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06170-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06170-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T10:11:12Z","timestamp":1745575872000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06170-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6170"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06170-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,10]]},"assertion":[{"value":"12 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The participants have consented to the submission of the case report to the journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Arjen Yousefi, Mark-David Levin and Jan J. Cornelissen declare no conflict of interests. Peter E. Westerweel has received research support and consultant fees from BMS\/Celgene and Novartis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}